TABLE 1.
Association between FGFR4 expression and patient clinicopathological factors at the time for hepatectomy
| Variable | FGFR4 positive (n = 16) | FGFR4 negative (n = 15) | P‐value |
|---|---|---|---|
| Age (years) | 70 (69–75) | 68 (63–76) | 0.2306 |
| Sex, male/female | 11/5 | 10/5 | 0.2268 |
| BMI (kg/m2) | 23.7 (22.5–26.0) | 22.1 (20.7–25.7) | 0.3626 |
| HBs‐Ag positive | 5 (31.3%) | 4 (26.7%) | 0.7786 |
| HCV‐Ab positive | 3 (20.0%) | 5 (31.3%) | 0.4723 |
| Albumin (g/dL) | 3.9 (3.6–4.4) | 3.8 (3.3–4.3) | 0.2547 |
| AFP (ng/mL) | 21.0 (5.1–283.3) | 12.9 (3.8–50.9) | 0.2535 |
| DCP (mAU/mL) | 158 (61.8–12991) | 53 (30.0–788.0) | 0.4727 |
| Tumor size (cm) | 4.0 (1.3–7.9) | 2.4 (1.4–5.0) | 0.8050 |
| Solitary/Multiple | 7/9 | 3/12 | 0.0601 |
| Poorly differentiation | 9 (56.3%) | 4 (26.7%) | 0.0921 |
| Microscopic vascular invasion | 6 (37.5%) | 3 (20.0%) | 0.2796 |
| Microscopic intrahepatic metastasis | 8 (50.0%) | 3 (20.0%) | 0.0768 |
| Child‐pugh score A/B/C | 16/0/0 | 15/0/0 | 0.2936 |
| BCLC staging 0/A/B/C/D | 2/13/1/0/0 | 3/11/1/0/0 | 0.8454 |
The data are presented as n (%) or median (interquartile).
Abbreviations: AFP, alpha‐fetoprotein; BCLC: Barcelona Clinic Liver Cancer; BMI, body mass index; DCP, des‐gamma‐carboxyprothrombin; HBs‐Ag, hepatitis B surface antigen; HCV‐Ab, hepatitis C virus antibody.